Competing drug pricing visions aired

On Tuesday, a group of six biotech CEOs and a generic drug industry advocate outlined competing visions to address controversies over the price of prescription drugs.

In a commentary posted on Forbes, the CEO group drew a sharp distinction between the innovative and generic drug industries. They called for "fixes to the current system for getting generic competitors to market" after innovator patent exclusivity has expired. ...